According to the WHO, nosocomial infection is defined as “an infection acquired in hospital by a patient who was admitted for a reason other than that infection”. An infection occurring in a patient in a hospital or other health care facility in whom the infection was not present or incubating at the time of admission. This includes infections acquired in the hospital but appearing after discharge, and also occupational infections among staff of the facility. The infection is caused due to bacteria, viruses, fungi and parasites. All hospital patients are susceptible to contract infection especially pediatric and geriatric section and immune compromised patient, due to extended stay in hospital, usage of indwelling catheters, some failure of health care provider or over dosage of antibiotics. The global nosocomial infection treatment market is anticipated to progress during the forecast period due to rising prevalence of nosocomial infections, increase in number of surgical procedures, and escalating focus on disinfection and sterilization technology.

The report titled “Global Nosocomial Infection Treatment Market - Growth, Share, Opportunities and Competitive Analysis, 2023–2030” offers strategic insights into the overall nosocomial infection treatment market along with the market size and estimates for the duration 2020 to 2030. The study covers in-depth analysis of multiple market segments based on type of product and different geographies. The infection types studied for analyzing the overall nosocomial infection treatment market is majorly segmented into ventilator associated pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA and others. The treatment types considered for analyzing the market are antibacterial, antifungal, antiviral treatments and others.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global nosocomial infection treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global nosocomial infection treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global nosocomial infection treatment market. In-depth competitive environment analysis and historical years market size data are also provided in the report.

Pneumonia and surgical site infection are the most common hospital acquired infections occupying the largest market share. Nosocomial pneumonia is observed in several varied groups. The patient on ventilators in ICU are more prone to infection, the rate of infection caused by pneumonia is 3% per day and associated with high fatality rate. Surgical site infection is the next followed up market, with incidence rate varying from 0.5% to 15% depending on type of operation and patient status. Bloodstream infection occupies almost 15% to 20% of nosocomial infections, affecting almost 1% of all hospitalized patients. It is associated with increased mortality rate and extended stay in an intensive care unit and hospital, therefore surveillance and prevention of BSI are high priorities. Urinary tract infection occurs due to usage of bladder catheter and associated with less morbidity compared to other nosocomial infection. MRSA is the second most common cause of HAIs reported to the NHSN. The CDC also estimates that 49% to 65% hospital acquired S. aureus infections reported to the NHSN are caused by methicillin resistant strains.

Antibiotic therapy is empirical in intensive care unit, due risk of emergence of emergency situations, infection severity in neutropenia, and large presence immunosuppressed and elderly patient. The selection of antibiotic therapy depends upon most common bacterial species causing infection, the pattern of the antibiotic resistance in particular hospital, patient clinical status and previous therapy. It covers both gram positive and gram negative bacteria. Initial antibiotic therapy includes ceftazimide plus vancomycin; if vancomycin is not used, mono-therapy with ceftazidime, imipenem, cefepime or meropenem is given. Multiple antibiotics are used when the organism develops resistant mutant, patient is immunocompromised, the higher serum activity is required, or blood culture consistently shows positive bacteria even after single therapy. The conventionally long used initial regimen of combination therapy recommended includes antipseudomonal penicillin plus aminoglycoside or an antipseudomonal cephalosporin (ceftazidime) plus an aminoglycoside. Antifungal drugs are used to treat fungal infection include amphotericin B, nystatin, ketoconazole, itraconazole, and fluconazole. Antiviral drugs used are Acyclovir, ganciclovir, foscarnet, and amantadine, which inhibit the growth or multiplication of the virus. Empiric antibiotic, antiviral and antifungal used to treat infection, avoid any further complication including organ damage.

North America currently dominates the regional global nosocomial infection market followed by Europe. The key drivers for North America market are rising prevalence of nosocomial infection, multi-drug resistant microbes, and rising demand for advanced therapeutics. The U.S is the major market in North America due to incessant technological advancements in surgical procedures, sterilization equipment and state of art health care facilities. Europe is the second largest market attributed to rise in geriatric population which is prone to nosocomial infection, government initiative to improve the healthcare facility and advancement in antimicrobial therapeutics. Asia Pacific is the fastest growing market due to factors such as increasing investment in health care facilities, rise in per capita income fueled with economic development, huge government investments in development of healthcare infrastructure, rising public awareness coupled with high prevalence of nosocomial infection.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Nosocomial Infection Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Nosocomial Infection Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Nosocomial Infection Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Nosocomial Infection Treatment market?
• Which is the largest regional market for Nosocomial Infection Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Nosocomial Infection Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Nosocomial Infection Treatment market worldwide?